|
?:abstract
|
-
Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with coronavirus disease 2019 (COVID-19) This study aimed to evaluate the factors influencing anti-factor Xa activity in COVID-19 patients receiving low molecular weight heparin (LMWH) We prospectively evaluated 80 COVID-19 patients, diagnosed using polymerase chain reaction test, who were admitted to our clinic and administered LMWH;LMWH (enoxaparin) was applied according to the weight, D-dimer levels, and clinical condition of patients Anti-factor Xa activity in blood, drawn 4 h after the 3rd dose of LMWH, was measured and an activity of 4%, 6 were in group 1 ((6/13) 46 2%), while 8 were in group 2 ((8/63) 11 9%);(p = 0 009), and all had a D-dimer level < 1 μg/mL (p = 0 03) ROC analysis for the presence of anticoagulation at subprophylactic level revealed an area under curve of 0 79 (95% CI: 0 64–0 93);p = 0 001) In conclusion;Elevated eosinophil count is related to lower anti-factor Xa activity in patients with COVID-19 receiving LMWH The clinical significance of the subprophylactic anti-factor Xa activity should be studied in COVID-19 patients (NCT04507282) FAU - Ari, Selma
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}